{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Oligodendroglioma-Astrocytoma&page=7",
    "query": {
      "condition": "Mixed Oligodendroglioma-Astrocytoma",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 231,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Oligodendroglioma-Astrocytoma&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Oligodendroglioma-Astrocytoma&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T06:01:03.569Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01032200",
      "title": "Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumors",
        "Nervous System Tumors",
        "Cognition Disorders",
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "Armodafinil",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2010-08-01",
      "completion_date": "2013-01-08",
      "has_results": true,
      "last_update_posted_date": "2021-09-28",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01032200"
    },
    {
      "nct_id": "NCT00064779",
      "title": "Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Mixed Oligoastrocytoma"
      ],
      "interventions": [
        {
          "name": "IL13-PE38QQR",
          "type": "DRUG"
        },
        {
          "name": "targeted fusion protein therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2003-07",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2011-06-06",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064779"
    },
    {
      "nct_id": "NCT02238496",
      "title": "Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumor, Recurrent",
        "Glioblastoma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Mixed Glioma"
      ],
      "interventions": [
        {
          "name": "Cytoreductive surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Perifosine",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Andrew B Lassman, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-12-08",
      "completion_date": "2021-02-14",
      "has_results": false,
      "last_update_posted_date": "2023-05-25",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02238496"
    },
    {
      "nct_id": "NCT00268385",
      "title": "Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Mixed Glioma",
        "Recurrent Adult Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2005-12-16",
      "completion_date": "2027-04-24",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00268385"
    },
    {
      "nct_id": "NCT00253721",
      "title": "Melphalan With BBBD in Treating Patients With Brain Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Lymphoma",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 21,
      "start_date": "1998-05",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253721"
    },
    {
      "nct_id": "NCT02444546",
      "title": "Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Astrocytoma",
        "Childhood Atypical Teratoid/Rhabdoid Tumor",
        "Diffuse Intrinsic Pontine Glioma",
        "Glioma",
        "Recurrent Childhood Anaplastic Oligodendroglioma",
        "Recurrent Childhood Brain Neoplasm",
        "Recurrent Childhood Glioblastoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Primitive Neuroectodermal Tumor",
        "Refractory Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Wild-type Reovirus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "10 Years to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-06-21",
      "completion_date": "2022-11-21",
      "has_results": false,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02444546"
    },
    {
      "nct_id": "NCT00303849",
      "title": "Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Oligoastrocytoma",
        "Anaplastic Oligodendroglioma",
        "Mixed Glioma",
        "Oligoastrocytoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mannitol",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Sodium Thiosulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 33,
      "start_date": "2005-09-15",
      "completion_date": "2021-03-12",
      "has_results": false,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Portland, Oregon",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303849"
    },
    {
      "nct_id": "NCT01110876",
      "title": "Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain Cancer",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2011-06",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110876"
    },
    {
      "nct_id": "NCT00006474",
      "title": "Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-03",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006474"
    },
    {
      "nct_id": "NCT01339039",
      "title": "Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Grade Glioma: Glioblastoma (GBM)",
        "High Grade Glioma: Gliosarcoma",
        "Anaplastic Astrocytoma (AA)",
        "Anaplastic Oligodendroglioma (AO)",
        "Mixed Anaplastic Oligoastrocytoma (AOA)"
      ],
      "interventions": [
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Patrick Y. Wen, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2011-12",
      "completion_date": "2017-04-08",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-10-23T06:01:03.569Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01339039"
    }
  ]
}